BPC-157 Benefits: The Most-Studied Healing Peptide

BPC-157 is a synthetic peptide researched for tissue repair. In animal and cell studies it is reported to drive new blood-vessel growth into slow-healing tissue such as tendon, ligament and gut lining, and to sensitise cells to growth hormone. Its researched register is local injury and gastrointestinal models. Human data is limited to small uncontrolled pilots, and it is banned in sport.

If you have spent any time around recovery peptides, BPC-157 is the first name you ran into. It is the one bodybuilders inject near a cranky tendon, the one biohackers swallow for a misbehaving gut, and the one with by far the deepest pile of research behind it of any peptide in the healing category. That last part is the whole pitch, and it is also where the honesty has to start: deep is not the same as proven in humans.

This guide lays out what BPC-157 actually does, what the data does and does not support, how people dose it, and the safety picture nobody selling it likes to dwell on. Primogen carries it on its own and inside three blends, so the goal here is to tell you straight what you are buying.

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid fragment of Body Protection Compound, a protein isolated from human gastric juice. BPC stands for Body Protection Compound, and BPC-157 is a partial sequence of that protein, made synthetically. The "stable" part of its old name (stable gastric pentadecapeptide) is the interesting bit: it resists breakdown in stomach acid in a way most peptides do not, reported to stay intact for over 24 hours in gastric juice. That stability is the reason oral dosing is studied for gut models at all, where for most peptides swallowing them is pointless.

It was originally developed by Pliva in Croatia under codes like PL-14736, with an inflammatory bowel disease research programme. That programme later passed through Barr and Teva and was quietly shelved, which matters for the evidence story below.

How does BPC-157 work?

In animal and cell studies, BPC-157 is reported to act mainly by promoting angiogenesis (new blood-vessel growth) and by sensitising tissue to growth hormone, mechanisms that show up in both tendon and gastrointestinal models. The mechanism is reasonably well mapped in preclinical work, which is why the same peptide is studied across connective tissue and the gut lining.

• Angiogenesis. BPC-157 is reported to upregulate VEGFR2 (a receptor that triggers blood-vessel growth) and to work through the nitric-oxide system (a signalling pathway that relaxes and widens blood vessels) to drive new blood vessels into tissue in animal models. Tendons and ligaments are poorly supplied with blood, which is the rationale researchers give for studying it in slow-healing connective tissue.
• Growth hormone receptor upregulation. In rat Achilles tendon fibroblasts, the cells that build connective tissue, BPC-157 increased growth hormone receptor expression, making those cells more responsive to endogenous GH (Chang et al., Molecules 2014). The reported mechanism sensitises tissue to the body's own GH rather than acting like injected GH.
• Cell migration and gut protection. In preclinical work it activates the FAK-paxillin pathway (a cell-signalling route) that drives fibroblasts to spread and migrate into a wound, shifts inflammatory macrophages (immune cells that clean up damage) toward a repair state, and protects the gastrointestinal lining (Sikiric et al., Front Pharmacol 2021). That gut-protective action is what the original Croatian IBD research programme was chasing.

One straight caveat worth knowing: a large share of the BPC-157 literature comes from a single research group (Sikiric and Seiwerth in Zagreb). A 2025 critical review (Jozwiak et al., Pharmaceuticals 2025) flagged that more than 80% of the published papers list those authors, which limits how confidently the findings generalise until independent labs replicate them. The mechanism is coherent. The independence of the evidence base is thinner than the volume suggests.

What is BPC-157 researched for?

BPC-157 is studied mainly in three areas: tendon, ligament and joint models, gastrointestinal models, and general tissue-repair and wound-healing models. The deepest preclinical file is musculoskeletal, and a handful of small human pilots exist in knee pain and bladder pain. The sections below cover what the research register is for each, and where the data actually sits.

What is BPC-157 researched for in tendon, ligament and joint repair?

Tendon, ligament and joint models are the headline research area and the community default. Bodybuilders and athletes use it for tendinopathy, rotator cuff issues, elbow pain, and joint niggles, usually injecting sub-Q (subcutaneously, into the fat just under the skin) near the injury site. The animal data on tendon and ligament healing is the most robust part of the file. The strongest human signal comes from a small pilot: in Lee & Padgett 2021, 12 patients with chronic knee pain were given a single intra-articular injection (delivered directly into the joint space); 11 of 12 reported significant relief, and 7 of 12 still reported relief more than six months later. That is the best human durability signal published, with the honest asterisk that it was a retrospective pilot of 12 people with no placebo control.

For how it stacks against the other recovery staple, see BPC-157 vs TB-500. The short version: they are a pair, not a choice. BPC-157 acts locally and fast, TB-500 acts systemically and slower, which is why they are so often run together.

What is BPC-157 researched for in gut healing?

Gastrointestinal models are BPC-157's signature research area, and the gut is the one place oral dosing is studied seriously. People use it for IBS-type symptoms, leaky gut, NSAID-induced stomach damage, and post-antibiotic disruption. Taken orally it is reported to act locally on the gut lining, which is the rationale for that route in gut-targeted research. The original Pliva Phase 2 programme in ulcerative colitis reported it was safe and well tolerated, though, as noted below, the efficacy results were never published.

One practical note worth being clear on: oral BPC-157 is studied as a locally-acting gut agent and is not reported to deliver systemic distribution for an external injury. If your problem is a tendon, the researched route is injecting near it; if your target is the gut, oral. For oral gut dosing, the community runs it either on an empty stomach (waiting about 30 minutes before eating) or with food, depending on tolerance.

What is BPC-157 researched for in general recovery and wellness?

General recovery and wellness is a third, softer research area, covering "body protection," surgical-recovery, and skin and wound-healing models, often studied alongside GHK-Cu and TB-500. That is the logic behind the GLOW and KLOW blends, which pair BPC-157 with TB-500, GHK-Cu, and in KLOW's case KPV, around tissue-repair, skin and collagen, and gut anti-inflammatory research register in one protocol.

What does the evidence on BPC-157 actually show?

BPC-157 has a huge preclinical base and almost no finished human data. There is no completed, published large human trial in any indication; what exists in humans is a few small, uncontrolled pilots. Here is the part the marketing skips.

• Animal studies: a large preclinical base covering tendon, ligament, muscle, gut, skin and more. A 2025 systematic review (Vasireddi et al., HSS J 2025) screened 544 BPC-157 articles published between 1993 and 2024; a narrower PubMed pull on 20 May 2025 returned over 190. Genuinely impressive in breadth, and the safety margin in animals is wide (the animal lethal dose was not reached even at very high amounts). The catch, covered above, is that more than 80% of those papers list Sikiric or Seiwerth, so the volume is bigger than the number of independent labs behind it.
• Human trials: there is no completed, published Phase 3, and no completed-and-published Phase 2 in any indication. The one properly powered Phase 2 (Pliva's ulcerative colitis programme) had its results buried when the development programme was killed. A Phase 1 in healthy volunteers (NCT02637284) had its results withdrawn from submission in 2016 with no public explanation.
• What does exist in humans is three small modern pilots, all from the same Florida clinic, none placebo-controlled: the knee-pain study above (n=12), an interstitial cystitis (a chronic bladder-pain condition) pilot (n=12) that reported 80 to 100% symptom resolution at six weeks (Lee et al. 2024), and an IV safety pilot (n=2) that reported no adverse effects (Lee & Burgess 2025).

So the fair framing is this: BPC-157 is the best-studied healing peptide by volume and the mechanism is coherent. It is also true that the human evidence is early-stage, uncontrolled, and the preclinical base leans heavily on one lab. Both things are true at once, and a vendor that only tells you the first half is selling you something.

How do you dose BPC-157?

The community and practitioner range is 250 to 500 mcg per day, sub-Q for systemic or local recovery and oral when the target is the gut, run in 4 to 8 week blocks. The figures below are what the community and practitioners use, not a clinical prescription, and they map to standard allometric scaling (the maths for converting an animal dose to a human one by body size) from the rat studies.

• General recovery / systemic: 250 to 500 mcg per day sub-Q, often split into a morning and evening dose.
• Acute musculoskeletal injury: a higher loading range early (up to roughly 600 to 1,000 mcg per day) sub-Q near the injury, then taper.
• Gut research register: 250 to 500 mcg per day, oral or sub-Q. Oral is the studied route when the target is the gut itself.

A worked reconstitution example. Take a 5 mg vial and add 2 mL of bacteriostatic water. That gives 5,000 mcg in 2 mL, or 2,500 mcg per mL. A standard insulin syringe is marked 0 to 100 units across 1 mL, so 1 mL = 100 units holds 2,500 mcg, and each unit holds 25 mcg. A 250 mcg dose is therefore 10 units (0.1 mL); a 500 mcg dose is 20 units (0.2 mL). At 250 mcg/day that 5 mg vial yields 20 doses.

It is a daily compound. The plasma half-life measured in animals is short, under about 30 minutes in rat and dog pharmacokinetic work (He et al., Front Pharmacol 2022), so dosing is frequent. You will see vendor copy claiming a "4-hour half-life", and that figure has no published source; the defensible argument is that downstream signalling outlasts the peptide in the blood, not that the half-life is long.

For the practical side, reconstituting with bacteriostatic water, swirling not shaking, drawing and injecting, there is a full walkthrough in how to reconstitute and dose. Two BPC-157-specific points: use bacteriostatic water only, and do not mix it in the same vial with TB-500 or GHK-Cu, because the binders and preservatives can degrade activity (a pre-formulated blend like the BPC-157 + TB-500 product is the manufacturer-stabilised exception, not a licence to DIY-mix in one vial).

How long should you cycle BPC-157?

Run it in blocks, not year-round: 4 weeks on / 4 off or 8 weeks on / 8 off, tied to an actual injury or goal, and not continuously beyond about 12 weeks. The community consensus, echoed by the practitioner sources in our knowledge base, is to treat it as a time-boxed tool rather than a permanent ancillary:

• 4 weeks on, 4 weeks off, or 8 weeks on, 8 weeks off.
• For an acute injury, run it until the injury resolves, then stop.
• Do not run it continuously beyond about 12 weeks.

The reasoning is partly caution around its vascular effects and partly that there is simply no long-term human safety data past 12 months to lean on. On surgery, the community picture is mixed rather than settled: some run BPC-157 around a procedure, others hold off in the first week or two afterwards to let the body's own acute inflammatory response do its job first. There is no human data to call it either way, so any peri-operative use is a conversation to have with the surgeon who knows your case.

What are the side effects and safety risks of BPC-157?

In animal and small human data BPC-157 is generally well tolerated, with standard blood panels largely unchanged and a wide safety margin in animals. There is no long-term human safety data. The real safety conversation is about a few specific things.

• The cancer caution. No study has shown BPC-157 causes cancer, and genotoxicity assays (lab tests for DNA damage) are negative. The concern is mechanical, not observed: the same angiogenesis and growth-factor pathways it acts on in repair models are pathways tumours can exploit. The practical position across our sources is consistent: do not use BPC-157 if you have an active or recently treated cancer, and get age- and risk-appropriate cancer screening before a long course. This caution sharpens if it is combined with GH or GH-secretagogues.
• Source quality and endotoxin. This is where sourcing stops being abstract. Poorly made "research only" peptide can carry LPS (bacterial endotoxin, a toxin shed by bacteria), which is inflammatory and, in the worst case, can provoke severe reactions. A clean product is not a luxury here, it is the safety margin. The honest aside the industry tends to stay quiet about: research peptides, including this one, mostly come out of China, and proper per-batch third-party testing is thin across the whole sector. Read the certificate of analysis on whatever you buy, and know exactly what it does and does not actually prove.
• It is not a structural fix. BPC-157 is researched as a tissue-repair agent; it is not reported to structurally reattach a fully torn tendon or ligament, or resolve a herniated disc. Those need proper diagnosis (imaging) and structural treatment. Reaching for a peptide instead of imaging on a suspected complete tear is how people lose time.
• Mood and dopamine. Some animal work touches on mood, and there are reports it may blunt the effect of dopaminergic stimulants (drugs that act on the brain's dopamine system) like Adderall or modafinil. The animal literature suggests a normalising rather than depressing effect on mood; the human picture is genuinely mixed and unproven either way.
• Reported in users: post-injection pain, redness or a burning sensation for a day or two, occasional headache, fatigue, or mild nausea with the oral form.

Is BPC-157 banned in sport?

Yes. BPC-157 is on the WADA Prohibited List under S0 (non-approved substances), banned at all times, in and out of competition, with no therapeutic use exemption available (WADA 2025 Prohibited List, S0). It is detectable in urine for several days (Cox et al., Drug Test Anal 2017), and real sanctions have been handed to athletes. If you are drug-tested in any capacity, this one is off the table.

Where does BPC-157 fit in your stack?

BPC-157 is run on its own for a tendon, ligament or gut target, or paired with TB-500 for a fast-plus-systemic recovery combination, or built into the GLOW and KLOW blends with GHK-Cu (and KPV) when the goal also covers skin and collagen. The breakdown:

• On its own: the default first choice for a tendon, ligament or gut target.
• With TB-500: the classic recovery pairing. Local and fast meets systemic and slower. Stocked as a pre-blended BPC-157 + TB-500 vial. Full comparison in BPC-157 vs TB-500.
• With GHK-Cu (and KPV): for recovery plus skin, collagen and gut, which is exactly what the GLOW and KLOW blends are built around. GLOW is BPC-157 + GHK-Cu + TB-500; KLOW adds KPV.